You are currently viewing imuno ace sars cov 2
imuno ace sars cov 2

imuno ace sars cov 2

Summary

The coronavirus disease-19 (COVID-19) is attributable to the extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The lengthy incubation interval of this new virus, which is usually asymptomatic but contagious, is a key cause for its speedy unfold internationally. At the moment, there isn’t a worldwide-approved therapy for COVID-19. Subsequently, the scientific and scientific communities have joint efforts to scale back the extreme impression of the outbreak. Analysis on earlier rising infectious illnesses have created helpful data that’s being exploited for drug repurposing and accelerated vaccine improvement. Nonetheless, it is very important generate data on SARS-CoV-2 mechanisms of an infection and its impression on host immunity, to information the design of COVID-19 particular therapeutics and vaccines appropriate for mass immunization. Nanoscale supply methods are anticipated to play a paramount function within the success of those prophylactic and therapeutic approaches. This Evaluate offers an outline of SARS-CoV-2 pathogenesis and examines immune-mediated approaches at the moment explored for COVID-19 remedies, with an emphasis on nanotechnological instruments.

imuno ace sars cov 2
imuno ace sars cov 2

Principal

The coronavirus disease-19 (COVID-19) pandemic attributable to extreme acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in Wuhan, China in December 2019. Since then, it has unfold globally, already infecting tens of millions of individuals worldwide. As of 30 June 2020, 213 nations have reported COVID-19 circumstances, with a complete quantity that reached above 10.Three million, essentially the most being within the USA (2.6 million), Brazil (1.Four million), Russia (640 thousand), India (548 thousand) and UK (314 thousand). USA has the best variety of deaths (126 thousand) adopted by Brazil (58 thousand), UK (44 thousand) and Italy (35 thousand). The worldwide case fatality fee throughout all communities is 4.9%.

Coronaviruses (CoVs) are enveloped viruses entrapping non-segmented, positive-sense and single-stranded ribonucleic acid (ssRNA). Their genome measurement ranges from 26 to 32 kb, being the biggest identified RNA virus. SARS-CoV-2 3’ terminus encodes structural proteins, together with spike (S) glycoproteins membrane (M) glycoproteins, in addition to envelope (E) and nucleocapsid (N) proteins). Along with the genes encoding structural proteins, there are particular genomic areas encoding for viral proteins required for replication, along with different non-structural proteins, such because the papain-like protease (PLpro) and coronavirus fundamental protease.

There seems to be genetic polymorphism of the ACE-2 with elevated threat of particular comorbidities—hypertension, heart problems, and diabetes (36, 37). The impression of allelic variants was reviewed in a computerized mannequin and it was demonstrated that it’s possible that some variations of ACE-2 will bind extra tightly to the SARS-COV-2 spike protein (38). The present speculation of autoimmunity postulates that increased ranges of soluble ACE-2, or augmented conformational binding to the spike protein, will increase the chance that the mixed entity might be processed by an antigen-presenting cell as a part of the virus. This may occasionally result in antibody manufacturing towards ACE-2, which triggers Kind 2 and three hypersensitivity responses, and Kind Four mobile immune concentrating on after the viral particles with connected soluble ACE-2 are processed by antigen-presenting cells.

Though most infectious illnesses goal each ends of the age spectrum due to both poorly-developed or impaired immune responses, COVID-19 disproportionately impacts the aged. Soluble ACE-2 can clarify the paradox of excessive mortality within the aged with no related raised toddler mortality fee. Elevated ranges of soluble ACE-2 have been famous in comorbidities related to increased mortality in COVID-19 (39). There are undetectable ranges within the serum of wholesome people (40) and a correlation exists between the prevalence of soluble ACE-2 and a person’s age (41). Latest analysis has indicated that soluble ACE-2 is essentially the most important threat issue for cardiometabolic mortality and might be related in COVID-19.

 

imuno ace
imuno ace

Acknowledgments

We want to categorical our gratitude to Else Koning for her helpful assist in the graphical design of the figures and Martin Bourgonje for critically proofreading the manuscript. As well as, we want to thank Dr Jan von der Thüsen (Division of Pathology, Erasmus Medical Heart, Rotterdam, The Netherlands) and Dr Hua Su (Division of Nephrology, Union Hospital, Wuhan, PR China) for kindly offering us with histological photos.

 

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial

E80028
  • EUR 388.30
  • EUR 860.20
  • 20 ul
  • 100 ul

Spike (SARS-CoV-2) Lentivirus

78010-2 500 µl x 2
EUR 2095
Description: Cell entry of SARS-CoV-2 depends on the binding of viral spike protein to cellular receptor ACE2. The SARS-CoV-2 Spike Lentivirus are replication incompetent, HIV-based, VSV-G pseudotyped lentiviral particles that are ready to be transduced into almost all types mammalian cells, including primary and non-dividing cells. The particles contain the full length SARS-CoV-2 spike gene (QHD43416.1) driven by an EF1a promoter._x000D_

3CL Protease (SARS-CoV-2)

100823-2 500 µg_x000D_
EUR 3360
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), expressed in an E. coli expression system, MW=34 kDa.

SARS-CoV-2 Spike S1 RBD Protein, Avi-His-tag

E80024
  • EUR 635.80
  • EUR 4995.10
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 RBD Protein, Mouse Fc-fusion

E80026
  • EUR 588.50
  • EUR 823.90
  • 20 ul
  • 50 ul

SARS-CoV-2 Spike S1 (16-685) Protein, Avi-His-tag

E80021
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 RBD (V367F) Protein, Avi-His-tag

E80023
  • EUR 635.80
  • EUR 3934.70
  • 100 ul
  • 1 ml

PLPro, His-tag (SARS-CoV-2)

100735-2 1 mg
EUR 3000
Description: SARS-Cov-2 papain-like protease (PLPro), part of a large replicase polyprotein 1ab (E1564-Y1882), GenBank Accession No. QHD43415, with a N-terminal His-tag, expressed in an E. coli expression system. MW=38 kDa.

NSP10/NSP16 Complex (SARS-CoV-2)

100747-2 1 mg
EUR 2500
Description: Complex of SARS-CoV-2 nonstructural protein 10 (NSP10), GenBank Accession No. YP_009725306.1, a.a. 1-139(full length), with N-terminal FLAG-tag, MW=16 kDa and SARS-CoV-2 nonstructural protein 16 (NSP16), Genbank Accession No. YP_009725311, a.a. 1-298(full length), with N-terminal His-tag, MW=34 kDa, co-expressed in a HEK293 cell expression system.

NSP7, His-tag (SARS-CoV-2)

100829-2 1 mg
EUR 2600
Description: SARS-CoV-2 nonstructural protein 7 (NSP7), Genbank Accession No.: YP_009742614, a.a. 1-84(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 10 kDa.

NSP8, His-tag (SARS-CoV-2)

100830-2 1 mg
EUR 2730
Description: SARS-CoV-2 nonstructural protein 8 (NSP8), Genbank Accession No.: YP 009725304.1, a.a. 1-198(full length), with C-terminal His-tag, expressed in an E. coli expression system. MW= 23 kDa.

Anti-Nucleocapsid Antibody (SARS-CoV-2 )

100861-2 100 µg
EUR 420
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Nucleocapsid (N) protein.

ORF9b, GST-Tag (SARS-CoV-2)

100962-2 1 mg
EUR 2720
Description: Recombinant ORF9b, full length, encompassing amino acids 1-97(end). This recombinant protein corresponds to SARS-CoV-2 accessory protein ORF9b. It was expressed in E.coli and contains an N-terminal GST tag and a prescission protease cleavage site. The recombinant protein is >90% pure following GST affinity purification.

SARS-CoV-2 Spike S1 (13-665) Protein, Fc Fusion, Avi-tag

E80020
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 (16-685) Protein, Fc Fusion, Avi-tag

E80022
  • EUR 635.80
  • EUR 4276.80
  • 100 ul
  • 1 ml

SARS-CoV-2 Spike S1 RBD Protein, Human Fc-Fusion, Avi-Tag

E80025
  • EUR 635.80
  • EUR 3934.70
  • 100 ul
  • 1 ml

3CL Protease (SARS-CoV-2) Assay Kit

79955-2 384 rxns.
EUR 1265
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease activity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps. 3CL inhibitor GC376 is also included as an inhibitor control.

Spike S1, Fc fusion (SARS-CoV-2)

100688-2 50 µg
EUR 505
Description: SARS-CoV-2 2019-nCoV Spike protein S1, also known as SARS-CoV s1 and coronavirus spike S1, GenBank Accession No. QHD43416.1, a.a. 16-685, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW= 160 kDa.

Anti-Spike S1 Antibody (SARS-CoV-2)

100715-2 100 µg
EUR 440
Description: Recombinant human monoclonal antibody recognizing the SARS-CoV-2 Spike RBD glycoprotein. This antibody cross-reacts with the Spike protein from the SARS-CoV virus.

Spike S2, Fc-Tag (SARS-CoV-2)

100895-2 500 µg_x000D_
EUR 1815
Description: SARS-CoV-2 Spike protein S2 subunit, also known as 2019-nCoV Spike S2, GenBank Accession No. MN908947, a.a. 686-1212, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=130 kDa.

SARS-CoV-2 Nucleocapsid Protein, Avi-His-tag

E80027-2 100 ul
EUR 4087.6

3CL Protease, Untagged (SARS-CoV-2) Assay Kit

78042-2 384 rxns.
EUR 1210
Description: The 3CL Protease Assay Kit is designed to measure 3CL Protease sactivity for screening and profiling applications, in a homogeneous assay with no time-consuming washing steps.

Spike (SARS-CoV-2) Pseudotyped Lentivirus (Luciferase Reporter)

79942-2 500 µl x 2
EUR 4405
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the firefly luciferase gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently measured via luciferase reporter activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_ _x000D_

Spike (SARS-CoV-2) Pseudotyped Lentivirus (eGFP Reporter)

79981-2 500 µl x 2
EUR 5245
Description: The pandemic coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). As the first step of the viral replication, the virus attaches to the host cell surface before entering the cell. The viral Spike protein recognizes and attaches to the Angiotensin-Converting Enzyme 2 (ACE2) receptor found on the surface of type I and II pneumocytes, endothelial cells, and ciliated bronchial epithelial cells. Drugs targeting the interaction between the Spike protein of SARS-CoV-2 and ACE2 may offer protection against the viral infection._x000D_The SARS-CoV-2 Spike Pseudotyped Lentivirus were produced with SARS-CoV-2 Spike (Genbank Accession #QHD43416.1) as the envelope glycoproteins instead of the commonly used VSV-G. These pseudovirions also contain the enhanced GFP gene driven by a CMV promoter, therefore, the spike-mediated cell entry can be conveniently determined via eGFP activity. The SARS-CoV-2 Spike pseudotyped lentivirus can be used to measure the activity of neutralizing antibody against SARS-CoV-2 in a Biosafety Level 2 facility._x000D_

Spike S1 RBD, His-tag (SARS-CoV-2)

100687-2 100 µg
EUR 520
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal His-tag, expressed in a CHO cell expression system. MW= 39 kDa.

Spike S1 RBD, Fc fusion (SARS-CoV-2)

100699-2 100 µg
EUR 520
Description: SARS-CoV-2 2019-nCoV Spike protein S1 subunit, receptor binding domain (RBD), also known as SARS-CoV-2 spike RBD, novel coronavirus spike RBD and nCoV spike RBD, GenBank Accession No. QHD43416.1, a.a. 319-541, with C-terminal Fc-tag, expressed in a CHO cell expression system. MW=50 kDa. This protein runs at a higher MW by SDS-PAGE due to glycosylation.

3CL Protease (Mpro), MBP-tag (SARS-CoV-2)

100707-2 1 mg
EUR 2535
Description: Severe acute respiratory Coronavirus 2 3C-like protease (SARS-CoV-2 3CL Protease), GenBank Accession No. YP_009725301, a.a. 1-306(full length), with an N-terminal MBP-tag, expressed in an E. coli expression system, MW=77.5 kDa.

Nucleocapsid Protein, Avi-His-tag (SARS-CoV-2)

100778-2 1 mg
EUR 2730
Description: SARS-CoV-2 nucleocapsid protein, also known as COVID-19 nucleocapsid and SARS-CoV-2 N protein, Genbank Accession No.: YP_009724397.2, a.a. 1-419(end), with C-terminal Avi-His-tag, expressed in a HEK293 cell expression system. MW= 48 kDa. This protein runs at a higher M.W. by SDS-PAGE due to glycosylation.

Recombinant SARS-CoV-2 Spike Glycoprotein(S) (D614G), Partial

E80028-2 100 ul
EUR 860.2

 

Leave a Reply